amikacin sulfate

Drug Name
Generic Name: amikacin sulfate Brand Name: Amikin Classifications: Anti-infective; Aminoglycoside Pregnancy Category: C
  • 250 mg/mL, 50 mg/mL injection
  • Semisynthetic derivative of kanamycin with broad range of antimicrobial activity that includes many strains resistant to other aminoglycosides.
  • Pharmacologic properties are essentially the same as those of gentamicin.
  • Appears to inhibit protein synthesis in bacterial cell and is usually bactericidal.
Therapeutic Effects
  • Effective against a wide variety of gram-negative bacteria including Escherichia coli, Enterobacter, Klebsiella pneumoniae, most strains of Pseudomonas aeruginosa, and many strains of Proteus species, Serratia, Providencia stuartii, Citrobacter freundii, Acinetobacter. Also effective against penicillinase- and non-penicillinase-producing Staphylococcus species, and against Mycobacterium tuberculosis and atypical mycobacteria.
  • Primarily for short-term treatment of serious infections of respiratory tract, bones, joints, skin, and soft tissue, CNS (including meningitis), peritonitis burns, recurrent urinary tract infections (UTIs).
  • Unlabeled Uses: Intrathecal or intraventricular administration, in conjunction with IM or IV dosage.
  • History of hypersensitivity or toxic reaction with an aminoglycoside antibiotic.
  • Safety during pregnancy (category C), lactation, neonates and infants, or use period exceeding 14 years old is not established.
Cautious Use
  • Impaired renal function; eighth cranial (auditory) nerve impairment; preexisting vertigo or dizziness, tinnitus, or dehydration; fever; older adults, premature infants, neonates and infants; myasthenia gravis; parkinsonism; hypocalcemia.
Route & Dosage
Moderate to Severe Infections
  • Adult: IV/IM 5–7.5 mg/kg loading dose, then 7.5 mg/kg q12h
  • Child: IV/IM 5–7.5 mg/kg loading dose, then 5 mg/kg q8h or 7.5 mg/kg q12h
  • Neonate: IV/IM 10 mg/kg loading dose, then 7.5 mg/kg q12–24h
Uncomplicated UTI
  • Adult: IV/IM 250 mg q12h
  • Use the 250 mg/mL vials for IM injection. Calculate the required dose and withdraw the equivalent number of mLs from the vial.
  • Give deep IM into a large muscle.
  • Verify correct IV concentration and rate of infusion with physician for neonates, infants, and children.
Adverse Effects
  • CNS: Neurotoxicity: drowsiness, unsteady gait, weakness, clumsiness, paresthesias, tremors, convulsions, peripheral neuritis.
  • Special Senses: Auditory–ototoxicity, high-frequency hearing loss, complete hearing loss (occasionally permanent); tinnitus; ringing or buzzing in ears;
  • Vestibular: dizziness, ataxia.
  • GI: Nausea, vomiting, hepatotoxicity.
  • Metabolic: Hypokalemia, hypomagnesemia.
  • Skin: Skin rash, urticaria, pruritus, redness.
  • Urogenital: Oliguria, urinary frequency, hematuria, tubular necrosis, azotemia.
  • Other: Superinfections.
  • Drug: ANESTHETICS, SKELETAL MUSCLE RELAXANTS have additive neuromuscular blocking effects; acyclovir, amphotericin B, bacitracin, capreomycin, cephalosporins, colistin, cisplatin, carboplatin, methoxyflurane, polymyxin B, vancomycin, furosemide, ethacrynic acid increase risk of ototoxicity and nephrotoxicity.
  • Peak: 30 min IV; 45 min to 2 h IM.
  • Distribution: Does not cross blood–brain barrier; crosses placenta; accumulates in renal cortex.
  • Elimination: 94%–98% excreted renally in 24 h, remainder in 10–30 d.
  • Half-Life: 2–3 h in adults, 4–8 h in neonates.
Nursing Considerations
Assessment & Drug Effects
  • Baseline tests: Before initial dose, C&S; renal function and vestibulocochlear nerve function (and at regular intervals during therapy; closely monitor in the older adult, patients with documented ear problems, renal impairment, or during high dose or prolonged therapy).
  • Monitor peak and trough amikacin blood levels: Draw blood 1 h after IM or immediately after completion of IV infusion; draw trough levels immediately before the next IM or IV dose.
  • Lab tests: Periodic serum creatinine and BUN, complete urinalysis. With treatment over 10 d, daily tests of renal function, weekly audiograms, and vestibular tests are strongly advised.
  • Monitor serum creatinine or creatinine clearance (generally preferred) more often, in the presence of impaired renal function, in neonates, and in the older adult; note that prolonged high trough (>8 mg/mL) or peak (>30–35 mg/mL) levels are associated with toxicity.
  • Monitor S&S of ototoxicity (primarily involves the cochlear (auditory) branch; high-frequency deafness usually appears first and can be detected only by audiometer); indicators of declining renal function; respiratory tract infections and other symptoms indicative of superinfections and notify physician should they occur.
  • Monitor for and report auditory symptoms (tinnitus, roaring noises, sensation of fullness in ears, hearing loss) and vestibular disturbances (dizziness or vertigo, nystagmus, ataxia).
  • Monitor & report any changes in I&O, oliguria, hematuria, or cloudy urine. Keeping patient well hydrated reduces risk of nephrotoxicity; consult physician regarding optimum fluid intake.
Patient & Family Education
  • Report immediately any changes in hearing or unexplained ringing/roaring noises or dizziness, and problems with balance or coordination.
  • Do not breast feed while taking this drug without consulting physician.


Very nice article. I read full article its very good information provided in this blog Herba Sleep Inducing Liquid 5ml

Very useful Information. Kalpana Naturals Provides one of the best product to increase our Immunity.
Buy our Best product
Immune Booster Oil
by Kalpana Naturals.

Post a Comment